急性心力衰竭的利尿组合疗法:一个更新的评论
Alessandro Villaschi1,2, Marta Pellegrino3, Gianluigi Condorelli1,2
1IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Current pharmaceutical design
|July 15, 2024
概括
循环利尿剂是急性心力衰竭的标准,但低于最佳的脱血和抵抗是常见的. 本综述探讨了利尿剂组合疗法,以改善结局,并管理心力衰竭患者的耐药性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 循环利尿剂是急性心力衰竭拥堵的主要治疗方法,指导方针建议使用.
- 低于最佳的脱率和经常发展的利尿剂耐药性限制了它们的有效性.
- 对利尿剂的反应不佳和残留拥堵与患者预后更差相关.
研究的目的:
- 对急性心力衰竭的利尿药联合治疗的现有证据进行审查.
- 探索避免或克服利尿剂耐药性的策略.
- 改善心力衰竭的解压策略和临床结果.
主要方法:
- 随机临床试验和关于利尿剂联合治疗的现有文献的综述.
- 对研究不同类型的利尿剂与循环利尿剂的使用进行研究的分析.
- 综合关于组合利尿剂方法的疗效和安全性的证据.
主要成果:
- 建议在急性心力衰竭时使用循环利尿剂,但耐药性是一个重大问题.
- 结合利尿类与循环利尿剂的临床试验显示出不同的结果.
- 目前还没有明确的策略来管理与组合治疗的利尿剂耐药性.
结论:
- 尽管对组合疗法有兴趣,但在急性心力衰竭中管理利尿剂耐药性的最佳方法仍未确定.
- 需要进一步的研究,以建立有效的利尿剂组合策略.
- 改善脱血和管理尿素抵抗对于更好的心力衰竭结果至关重要.
相关概念视频
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Antihypertensive Drugs: Action of Diuretics
665
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
665
Antihypertensive Drugs: Thiazide-Class Diuretics
595
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
595


